Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/18/26 Corxel Pharmaceuticals VCT 220 for Obesity Subscribers Only Subscribers Only Subscribers Only
5/15/26 Aardvark Therapeutics (AARD) ARD-101 for Prader-Willi Syndrome Subscribers Only Subscribers Only Subscribers Only
5/15/26 Candel Therapeutics (CADL) CAN-2409 for Prostate Cancer Subscribers Only Subscribers Only Subscribers Only
5/15/26 Palvella Therapeutics (PVLA) Qtorin for Vascular Disease Subscribers Only Subscribers Only Subscribers Only
5/15/26 Palvella Therapeutics (PVLA) Qtorin for Lymphatic Malformation (LM) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
07/31/2025 Subscribers Only Subscribers Only Regulatory - IND/CTA Filing
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update